A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 3

.The relationship between different variables and OS for breast cancer patients with nonpCR.

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Age (≤49 vs. >49)	1.22 (0.77-1.94)	0.401
Position (left vs. right)	1.31 (0.82-2.08)	0.253
Menopause (no vs. yes)	1.36 (0.86-2.16)	0.194
Parturition (0 vs. 1)	0.40 (0.22-0.74)	0.004	0.41 (0.22-0.77)	0.006
Parturition (0 vs. ≥2)	0.73 (0.38-1.43)	0.362	0.67 (0.33-1.34)	0.258
OS.INPS (≤0.3917 vs. >0.3917)	2.81 (1.75-4.51)	<0.001	2.41 (1.45-4.01)	<0.001
OS.L (≤1.48 vs. >1.48)	0.60 (0.35-1.02)	0.057
OS.N (≤5.9 vs. >5.9)	2.38 (1.31-4.35)	0.005	1.67 (0.85-3.25)	0.134
OS.M (≤0.36 vs. >0.36)	1.31 (0.79-2.16)	0.292
OS.HB (≤132 vs. >132)	0.63 (0.4-1.01)	0.053
OS.P (≤313 vs. >313)	1.63 (0.9-2.98)	0.11
OS.ALB (≤46.3 vs. >46.3)	1.28 (0.77-2.12)	0.348
OS.GLOB (≤34.8 vs. >34.8)	1.67 (0.95-2.95)	0.077
Clinical T stage (1 vs. 2)	0.59 (0.28-1.26)	0.173	0.68 (0.32-1.45)	0.315
Clinical T stage (1 vs. 3)	0.88 (0.38-2.05)	0.771	0.95 (0.41-2.21)	0.905
Clinical T stage (1 vs. 4)	5.Nn(1.37-19.5)	0.015	5.70 (1.43-22.8)	0.014
Clinical N stage (0 vs. 1)	1.48 (0.32-6.86)	0.615
Clinical N stage (0 vs. 2)	1.19 (0.29-4.91)	0.81
Clinical N stage (0 vs. 3)	1.5° (0.35-6.42)	0.588
Clinical TNM stage (II vs. III)	0.92 (0.47-1.79)	0.806
Molecular subtype (luminal A vs. B)	1.43 (0.71-2.87)	0.311
Molecular subtype (luminal A vs. HER2-OE)	0.82 (0.34-1.96)	0.653
Molecular subtype (luminal A vs. TNBC)	1.35 (0.59-3.09)	0.472
ER (negative vs. positive)	1.28 (0.79-2.1)	0.317
PR (negative vs. positive)	1.09 (0.68-1.73)	0.721
HER-2 (negative vs. low expression)	1.07 (0.62-1.82)	0.818
HER-2 (negative vs. positive)	0.78 (0.44-1.4)	0.408
Ki-67 (<20% vs. ≥20%)	1.49 (0.92-2.4)	0.107
P53 (negative vs. positive)	1.4 (0.85-2.29)	0.187
Cycle (≤4 vs. >4)	1.23 (0.78-1.97)	0.374